BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Heart Warning Added to Pfizer Inc. (PFE)s "Z-Pak" Antibiotic by FDA


3/13/2013 7:41:25 AM

Doctors should be aware of potential risks to patients with heart conditions when prescribing the antibiotic azithromycin, U.S. regulators said. The Food and Drug Administration today updated the labeling information on the drug to reflect increased risk of fatal irregular heartbeats in patients. Research published last year found that the pills, used to treat infections, caused a small increase in cardiovascular deaths, especially among people with a higher risk of heart problems. “Health-care professionals should consider the risk of fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk,” the FDA said in a statement today on the label change. The agency said azithromycin isn’t alone in carrying heart risks. Zithromax is made by Pfizer Inc. (PFE), the world’s largest drugmaker, and multiple generic manufacturers, and sometimes goes by the names Zithromax, Zmax or Z-Pak. The medicine generated (PFE) about $435 million for New York-based Pfizer in 2012. It’s prescribed to treat bacterial infections of the respiratory system and urinary tract and for tonsillitis.

Read at BusinessWeek
Read at Los Angeles Times
Read at RTT News
Read at USA Today
Read at Daily Mail UK

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES